Clinical Trials
3 trialsNCT06470451 2026-04-03
FLASH2
Soligenix
Phase 3 Recruiting
NCT05872854 2026-02-09
RW-HPN-MF-01
Abramson Cancer Center at Penn Medicine
Phase 2 Completed
NCT02448381 2022-04-15
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)
Soligenix
Phase 3 Completed